
Dropprint Genomics
Dropprint Genomics is a YC Winter 2020 (W20) company. Based in San Francisco, CA, USA. Team of 2.
About Dropprint Genomics
Summary
Dropprint Genomics builds software for single-cell genomics analysis, serving researchers and pharmaceutical teams who need to study the activity of individual cells rather than averaged signals across a population. The platform combines a database of immune cells spanning healthy, cancerous, and autoimmune states with machine-learning models to automate target discovery. This replaces manual, cost-prohibitive sequencing workflows and the bespoke computational pipelines labs previously had to build in-house.
Go-to-market
Pharma and biotech partners pay for access to Dropprint Genomics' database and analytical tools, with growth driven through paid research partnerships rather than self-serve adoption.
From the Y Combinator listing
The better way to run single cell genomics
Who we are? We write software that understands the activity of individual cells as opposed to all cells. This approach is novel because we are no longer looking at average signals and can be precise. It is like a police person trying to identify the speeding car, they won’t find it if they look at all the cars at once, rather they need to look at the speed of each individual car. This is the beauty of single cell genomics, we can now identify that speeding car. Why now? The biggest barrier for entry into the single cell genomics market are cost and data analysis. To that end, we have reduced the cost by 10-fold and built the computational infrastructure for scalability. Although single cell sequencing has only been around for about five years, we come from one of the top single cell genomics labs and were the first to process and analyze millions of immune cells. Thanks to our software solutions, we have been able to bring big data solutions to the immune system. Where are we and where are we going? We have generated a database of over 1 million immune cells spanning healthy, cancerous, and autoimmune immune cells and are growing through paid partnerships. Harnessing out database and ML software, we can take a data-centric approach for better target discovery. Fortunately, as our database continues to grow, our models will continue to learn for more precise, unbiased, and automated single cell genomics. Thank you!
Facts
- Healthcare / Healthcare -> Drug Discovery and Delivery
- San Francisco, CA, USA
- 2
- Acquired
- Early
Founders (3)
- Jimmie Ye
- Meena Subramaniam
- Rachel Gate
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works